IP Library Granted Patent US 8,466,120
Granted Patent B2
US 8,466,120 · App. 12/797,643 · Granted Jun 18, 2013

Oligomeric compounds and compositions for use in modulation of pri-miRNAs

Inventors: Bridget Lollo (Encinitas, CA); Ravi Jain (Carlsbad, CA)
Assignee: Regulus Therapeutics Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,466,120
App. No.
12/797,643
Granted
Jun 18, 2013
Kind
B2
Abstract

Compounds, compositions and methods are provided for modulating the levels expression, processing and function of pri-miRNAs. In particular, methods and compounds are provided for the modulation of the levels, expression, processing or function of polycistronic pri-miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and pri-miRNAs. Further provided are methods for selectively modulating pri-miRNA levels in a cell. Also provided are methods for identifying oligomeric compounds that result in increase pri-miRNA levels when contacted with a cell.

Claims (12)

1. A method of increasing the amount of pri-miR-21 in a cell comprising:

contacting the cell with an oligomeric compound comprising an oligonucleotide consisting of 15 to 30 linked nucleosides and having a nucleobase sequence selected from SEQ ID NOs: 57 to 60, 65 to 70, and 74, whereby the amount of pri-miR-21 in the cell is increased.

2. The method of claim 1 wherein the oligonucleotide consists of 17 to 25 linked nucleosides.

3. The method of claim 1 wherein the oligomeric compound consists of an oligonucleotide.

4. The method of claim 1 wherein at least one nucleoside of the oligonucleotide comprises a sugar modification.

5. The method of claim 4 wherein each nucleoside of the oligonucleotide comprises a sugar modification.

6. The method of claim 5 wherein the sugar modification is 2′-O-methoxyethyl.

7. The method of claim 1 wherein at least one internucleoside linkage is a modified internucleoside linkage.

8. The method of claim 1 wherein each internucleoside linkage is a modified internucleoside linkage.

9. The method of claim 8 wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.

10. The method of claim 1 wherein the oligonucleotide comprises at least one cytosine, wherein the cytosine is a 5-methylcytosine.

11. The method of claim 10 wherein each cytosine is a 5-methylcytosine.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded May 14, 2024
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT AND LENDER
To: REGULUS THERAPEUTICS INC.
Reel/Frame 067402/0782 →
SECURITY INTEREST Recorded Aug 8, 2018
From: REGULUS THERAPEUTICS INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT AND LENDER
Reel/Frame 046748/0561 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2011
From: ESAU, CHRISTINE; LOLLO, BRIDGET; BENNETT, C. FRANK; FREIER, SUSAN M.; GRIFFEY, RICHARD H.; BAKER, BRENDA F.; VICKERS, TIMOTHY A.; MARCUSSON, ERIC G.; KOLLER, ERICH; SWAYZE, ERIC E.; JAIN, RAVI; BHAT, BALKRISHEN; PERALTA, EIGEN R.
To: ISIS PHARMACEUTICALS, INC.
Reel/Frame 026107/0384 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2011
From: ISIS PHARMACEUTICALS, INC.
To: REGULUS THERAPEUTICS, LLC
Reel/Frame 026107/0491 →
CHANGE OF NAME Recorded Apr 11, 2011
From: REGULUS THERAPEUTICS, LLC
To: REGULUS THERAPEUTICS INC.
Reel/Frame 026108/0016 →
Continuity (8)
Continuation 11329992 · Jan 10, 2006
Continuation In Part 10909125 · Jul 30, 2004
Provisional Application 60492056 · Jul 31, 2003
Provisional Application 60516303 · Oct 31, 2003
Provisional Application 60531596 · Dec 19, 2003
Provisional Application 60562417 · Apr 14, 2004
Provisional Application 60612831 · Jan 10, 2005
Related Publication 20100249215A1 · Sep 30, 2010